^von Itzstein M (December 2007). “The war against influenza: discovery and development of sialidase inhibitors”. Nature Reviews. Drug Discovery6 (12): 967-74. doi:10.1038/nrd2400. PMID18049471.
^Palese P, Tobita K, Ueda M, Compans RW (October 1974). “Characterization of temperature sensitive influenza virus mutants defective in neuraminidase”. Virology61 (2): 397-410. doi:10.1016/0042-6822(74)90276-1. PMID4472498.
^Schmidt PM, Attwood RM, Mohr PG, Barrett SA, McKimm-Breschkin JL (2011) "A Generic System for the Expression and Purification of Soluble and Stable Influenza Neuraminidase". PLoS ONE 6(2): e16284. [1]doi:10.1371/journal.pone.0016284
^Taylor NR, von Itzstein M (March 1994). “Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis”. Journal of Medicinal Chemistry37 (5): 616-24. doi:10.1021/jm00031a011. PMID8126701.
^Drickamer, Kurt; Taylor, Maureen P. (2006). Introduction to glycobiology. Oxford [Oxfordshire]: Oxford University Press. pp. 177-178. ISBN0-19-928278-1
^Dyason, Jeffrey C.; Itzstein, Mark von (2001). “Anti-Influenza Virus Drug Design: Sialidase Inhibitors”. Australian Journal of Chemistry54 (11): 663-670. doi:10.1071/CH01173.
^Fgedi, Pťer (2006). The organic chemistry of sugars. Washington, DC: Taylor & Francis. pp. 822-823. ISBN0-8247-5355-0
^von Itzstein M, Wu WY, Jin B (June 1994). “The synthesis of 2,3-didehydro-2,4-dideoxy-4-guanidinyl-N-acetylneuraminic acid: a potent influenza virus sialidase inhibitor”. Carbohydrate Research259 (2): 301-5. doi:10.1016/0008-6215(94)84065-2. PMID8050102.
^Magesh S, Moriya S, Suzuki T, Miyagi T, Ishida H, Kiso M (January 2008). “Design, synthesis, and biological evaluation of human sialidase inhibitors. Part 1: selective inhibitors of lysosomal sialidase (NEU1)”. Bioorganic & Medicinal Chemistry Letters18 (2): 532-7. doi:10.1016/j.bmcl.2007.11.084. PMID18068975.